Format

Send to

Choose Destination
Br J Pharmacol. 2013 Aug;169(7):1430-46. doi: 10.1111/bph.12222.

Efficacy and ligand bias at the μ-opioid receptor.

Author information

1
School of Physiology and Pharmacology, University of Bristol, Bristol, UK. E.Kelly@bristol.ac.uk

Abstract

In order to describe drug action at a GPCR, a full understanding of the pharmacological terms affinity, efficacy and potency is necessary. This is true whether comparing the ability of different agonists to produce a measurable response in a cell or tissue, or determining the relative ability of an agonist to activate a single receptor subtype and produce multiple responses. There is a great deal of interest in the μ-opioid receptor (MOP receptor) and the ligands that act at this GPCR not only because of the clinically important analgesic effects produced by MOP agonists but also because of their liability to induce adverse effects such as respiratory depression and dependence. Our understanding of the mechanisms underlying these effects, as well as the ability to develop new, more effective MOP receptor drugs, depends upon the accurate determination of the efficacy with which these ligands induce coupling of MOP receptors to downstream signalling events. In this review, which is written with the minimum of mathematical content, the basic meaning of terms including efficacy, intrinsic activity and intrinsic efficacy is discussed, along with their relevance to the field of MOP receptor pharmacology, and in particular in relation to biased agonism at this important GPCR.

KEYWORDS:

GPCR; efficacy; intrinsic efficacy; ligand bias; μ-opioid receptor

PMID:
23646826
PMCID:
PMC3724102
DOI:
10.1111/bph.12222
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center